{
  "pmcid": "3889447",
  "sha256": "7b3b7c0214f87ee40ab27a0c0fe4ec90e6043213aa311d1a3254999cb09440ca",
  "timestamp_utc": "2025-11-09T22:40:01.073252+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 15.020727213962513,
    "reading_ease": 15.48761312217195,
    "word_count": 221
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Intraosseous Regional Administration of Vancomycin in Total Knee Arthroplasty"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "30 patients undergoing primary TKA were randomised"
      },
      "Participants": {
        "score": 1,
        "evidence": "30 patients undergoing primary TKA"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised to receive either 250 mg or 500 mg vancomycin via IORA or 1 g via systemic administration"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the efficacy of low-dose intraosseous regional administration (IORA) of vancomycin compared to systemic administration"
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "The primary outcome was tissue concentration of vancomycin, measured during the procedure."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was performed using a computer-generated sequence, and allocation was concealed using sealed envelopes."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "30 patients undergoing primary TKA were randomised"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Mean vancomycin concentrations in subcutaneous fat were 14 μg/g in the 250-mg IORA group, 44 μg/g in the 500-mg IORA group, and 3.2 μg/g in the systemic group."
      },
      "Harms": {
        "score": 1,
        "evidence": "One patient in the systemic group developed red man syndrome. No other adverse events were reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 13,
    "max_score": 25
  }
}